Stock Analysis
Incyte Corporation (INCY) Stock Analysis
Incyte Corporation (INCY) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Incyte Corporation (INCY) currently has an AIQ Score of 64/100, indicating a neutral setup. Quality is the strongest factor at 90/100. Momentum is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
INCY at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $113.44 |
| AIQ Score | 64/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $25.34B |
| P/E Ratio (TTM) | 15.38 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $2.92 |
| Revenue (quarter ended 2026-06-30) | $1.67B |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.77 |
| Volume | 1.39M |
| 52-week range | $84.02-$132.60 |
| RSI 14 | 41.43 |
| 50-Day SMA | $121.44 |
| 200-Day SMA | $107.71 |
| Analyst Price Target | $124.67 |
| Next Earnings | Oct 29, 2026 |
INCYIncyte Corporation
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum42
- Value52
- Quality90
- Risk resilience73
- Sentiment69
INCY Stock Analysis Summary
Incyte Corporation (INCY) currently has an AIQ Score of 64/100, indicating a neutral setup. Quality is the strongest factor at 90/100. Momentum is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, INCY has AIQ Score of 64/100 with Quality base of 90/100 and fading Momentum at 42/100. Wait for component alignment before adding exposure.
Quality (90/100) leads while Momentum (42/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -2.72% stock move · INCY classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is INCY Bullish or Bearish Right Now?
INCY currently has a neutral overall setup. Quality is the strongest factor at 90/100, while Momentum is weakest at 42/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 90/100.
- - Risk Resilience is supportive at 73/100.
- - Analyst target implies +9.90% upside from the latest quote.
- - Momentum is weak at 42/100.
- - Technical consensus has more sell votes than buy votes (28 vs 9).
Current Consensus
INCY's Technical Analysis Consensus is currently Sell, with 9 buy, 8 neutral, and 28 sell votes. INCY's 14-day RSI is 41.43, which places the stock in a weaker momentum range. INCY's beta is 0.77, indicating lower market sensitivity than the broad market.
What Changed in INCY?
The largest recent change in INCY is Momentum moving up by 12.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the INCY Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
INCY Decision Framework
Public evidence layers, setup checks, and risk context for Incyte Corporation.
Incyte Corporation (INCY) Stock Analysis
Incyte Corporation has an AIQ Score of 64/100 in a Neutral regime. Quality is strongest at 90/100. Beta is 0.74, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | INCY is in a Neutral AIQ regime with score 64/100. |
| Signal Conflict | The primary conflict is that quality leads at 90/100 while momentum lags at 42/100. |
| Factor Evidence | Momentum 42/100 · Value 52/100 · Quality 90/100 · Risk 73/100 · Sentiment 69/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 90/100.
Momentum is 42/100 and RSI (14) is 41.4.
INCY is in a Neutral regime at 64/100.
Risk factor is 73/100 with beta 0.74 and annual volatility 33.52%.
Current conflict: quality leads at 90/100 while momentum lags at 42/100.
INCY Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
INCY Fundamentals
INCY valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
INCY Technical Analysis
INCY technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
INCY Stock Catalysts
Track INCY earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
INCY Dividend Analysis
INCY dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
INCY Financial Data
INCY revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
INCY Risk Analysis
INCY volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
INCY Stock News
INCY stock news, market tone, recent headlines, and catalyst context.
INCY vs Large Cap Pharma Peers
Current peer cohort: INCY · JNJ · LLY · MRK · MRNA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| INCY Current stock | 64/100 | 52/100 | 42/100 | 73/100 | 0.87 | 33.52% | Current |
| JNJ Johnson & Johnson | 52/100 | 39/100 | 48/100 | 48/100 | 1.31 | 20.43% | INCY vs JNJ |
| LLY Eli Lilly | 62/100 | 26/100 | 95/100 | 50/100 | 1.36 | 34.89% | INCY vs LLY |
| MRK Merck | 47/100 | 27/100 | 71/100 | 44/100 | 1.88 | 29.63% | INCY vs MRK |
| MRNA Moderna | 47/100 | 34/100 | 82/100 | 54/100 | 1.67 | 193.78% | INCY vs MRNA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching INCY
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for INCY
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
INCY Stock FAQ
What is INCY stock price today?
Incyte Corporation's current stock price is $113.44. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is INCY bullish or bearish right now?
INCY's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is INCY's market cap?
INCY's market cap is $25.34B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is INCY's current P/E ratio?
INCY's current P/E ratio is 15.38 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is INCY's RSI?
INCY's 14-day RSI is 41.43 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is INCY above its 50-day and 200-day moving averages?
INCY is -6.58% from its 50-day SMA and 5.32% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is INCY's next earnings date?
INCY's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does INCY pay a dividend?
INCY's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.